Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Cash (2016 - 2025)

Ocular Therapeutix has reported Change in Cash over the past 13 years, most recently at $392.3 million for Q4 2025.

  • Quarterly results put Change in Cash at $392.3 million for Q4 2025, up 1217.06% from a year ago — trailing twelve months through Dec 2025 was $345.0 million (up 75.87% YoY), and the annual figure for FY2025 was $345.0 million, up 75.87%.
  • Change in Cash for Q4 2025 was $392.3 million at Ocular Therapeutix, up from -$46.4 million in the prior quarter.
  • Over the last five years, Change in Cash for OCUL hit a ceiling of $392.3 million in Q4 2025 and a floor of -$46.4 million in Q3 2025.
  • Median Change in Cash over the past 5 years was -$16.3 million (2021), compared with a mean of $25.4 million.
  • Biggest five-year swings in Change in Cash: crashed 197.2% in 2021 and later soared 1333.48% in 2024.
  • Ocular Therapeutix's Change in Cash stood at -$15.1 million in 2021, then decreased by 23.37% to -$18.6 million in 2022, then skyrocketed by 557.14% to $85.3 million in 2023, then tumbled by 141.19% to -$35.1 million in 2024, then soared by 1217.06% to $392.3 million in 2025.
  • The last three reported values for Change in Cash were $392.3 million (Q4 2025), -$46.4 million (Q3 2025), and $41.5 million (Q2 2025) per Business Quant data.